Novartis
Novartis expands immuno-oncology programme
January 11, 2016Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology
Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
Novartis and Qualcomm to develop smart inhaler technology for COPD
January 8, 2016Manufacturing and Production, Medical Communications COPD, Novartis, Qualcomm Life, breezhaler, digital inhaler, qualcomm
Novartis has enlisted Qualcomm life to help the pharma giant develop the ‘next generation’ of its Breezhaler device for patients …
Novartis’ Cosentyx shows benefits in Phase III AS trials
January 4, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis
Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …
EMA adds warning label to Novartis’ MS treatment Gilenya
December 22, 2015Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …
US ‘star’ Bradner to head Novartis Institute of Biomedical Research
December 17, 2015Research and Development James Bradner, Jay Bradner, Mark Fishman, Novartis, Novartis Institute for Biomedical Research
Novartis has hired James ‘Jay’ Bradner, from Harvard’s Dana-Farber Cancer Institute, to head its Institutes for Biomedical Research from 1 …
Novartis earns provisional NICE yes for Entresto
December 11, 2015Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure
NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
Novartis reaches 300 million free antimalarial treatments
December 9, 2015Manufacturing and Production, Research and Development Coartem, Novartis, antimalarial treatment, malaria, non-profit
Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments, having supplied its Coartem dispersible without profit to …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
NICE backtracks on Novartis Farydak decision
December 4, 2015Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat
NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Bayer and Novartis to debut new data at ASH 2015
November 30, 2015Research and Development, Sales and Marketing American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology
Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …
Novartis and Amgen drugs signed-off by European Commission
November 24, 2015Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto
The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …
FDA accepts regulatory submission for Novartis biosimilar
November 18, 2015Research and Development, Sales and Marketing Neulasta, Novartis, Sandoz, biosimilar, pegfilgrastim
Novartis’ generics unit Sandoz has announced it has had its Biologics License Application (BLA) for a proposed biosimilar to Amgen’s …
Novartis misses Q3 forecast with $390m settlement payment, strong dollar
October 27, 2015Manufacturing and Production, Sales and Marketing Alcon, Novartis, Sandoz
Novartis reported lower-than anticipated third quarter earnings on Tuesday, hit by the $390 million settlement it has agreed to pay …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
